Alpha 2.0
Login Register
» Authors » Jonathan Hartzel

Jonathan Hartzel

Explore the profile of Jonathan Hartzel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 393
Followers 0
Related Specialties
Allergy & Immunology
Pediatrics
General Medicine
Top 10 Co-Authors
Barbara J Kuter
Luwy K Musey
Florian Schodel
Jon E Stek
Henry Shinefield
Jianing Li
Richard T Wiedmann
Rocio D Marchese
Jin Xu
Steve Black
Published In
Vaccine
Pediatr Infect Dis J
Hum Vaccin Immunother
Pediatrics
Ann Intern Med
Affiliations
Soon will be listed here.
Recent Articles
1.
A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China
Chen S, Ying Z, Liu Y, Li Y, Yu Y, Huang M, et al.
Hum Vaccin Immunother . 2024 Mar; 20(1):2324538. PMID: 38509699
This open-label, randomized, phase 3 study in China (V260-074; NCT04481191) evaluated the immunogenicity and safety of concomitant and staggered administration of three doses of an oral, live, pentavalent rotavirus vaccine...
2.
Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials
Simon J, Kennedy S, Mahon B, Dubey S, Grant-Klein R, Liu K, et al.
Vaccine . 2022 Oct; 40(46):6599-6606. PMID: 36208978
Background: ERVEBO®, a live recombinant vesicular stomatitis virus (VSV) vaccine containing the Zaire ebolavirus glycoprotein (GP) in place of the VSV GP (rVSVΔG-ZEBOV-GP), was advanced through clinical development by Merck...
3.
Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials
Grais R, Kennedy S, Mahon B, Dubey S, Grant-Klein R, Liu K, et al.
Lancet Microbe . 2022 May; 2(2):e70-e78. PMID: 35544244
Background: Establishment of immune correlates of protection can provide a measurable criterion for assessing protection against infection or disease. For some vaccines, such as the measles vaccine, antibodies serve as...
4.
Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial
Vanhoutte F, Liu W, Wiedmann R, Haspeslagh L, Cao X, Boundy K, et al.
EBioMedicine . 2022 Jan; 75:103811. PMID: 35042081
Background: We report on the safety and immunogenicity of V591, a measles vector-based SARS-CoV-2 vaccine candidate. Methods: In this multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial, healthy adults with no...
5.
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)
Severance R, Schwartz H, Dagan R, Connor L, Li J, Pedley A, et al.
Hum Vaccin Immunother . 2021 Nov; 18(1):1-14. PMID: 34726574
and influenza viruses are associated with significant morbidity and mortality in older adults. Concomitant vaccination against these agents reduces hospitalization and mortality rates. This phase 3 trial evaluated safety, tolerability,...
6.
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH)
Song J, Chang C, Andrews C, Diez-Domingo J, Oh M, Dagan R, et al.
Vaccine . 2021 Sep; 39(43):6422-6436. PMID: 34489128
Background: Streptococcus pneumoniae causes pneumococcal disease, and older adults are at an increased risk. Sequential vaccination of 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) is...
7.
Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older
Buchwald U, Andrews C, Ervin J, Peterson J, Tamms G, Krupa D, et al.
Hum Vaccin Immunother . 2021 May; 17(8):2678-2690. PMID: 34019468
In most countries worldwide, pneumococcal conjugate vaccines have been included in the infant immunization program, resulting in a significant reduction in the burden of pneumococcal disease in children and adults....
8.
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials
Mehrotra D, Janes H, Fleming T, Annunziato P, Neuzil K, Carpp L, et al.
Ann Intern Med . 2020 Oct; 174(2):221-228. PMID: 33090877
Several vaccine candidates to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) have entered or will soon enter large-scale, phase 3, placebo-controlled randomized...
9.
Using artificial intelligence tools in answering important clinical questions: The KEYNOTE-183 multiple myeloma experience
Liao J, Farooqui M, Marinello P, Hartzel J, Anderson K, Ma J, et al.
Contemp Clin Trials . 2020 Oct; 99:106179. PMID: 33086159
The phase III, randomized, active-controlled, multicenter, open-label KEYNOTE-183 study (NCT02576977) evaluating pomalidomide and low dose dexamethasone (standard-of-care [SOC]) with or without pembrolizumab in patients with refractory or relapsed and refractory...
10.
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants
Greenberg D, Hoover P, Vesikari T, Peltier C, Hurley D, McFetridge R, et al.
Vaccine . 2018 Sep; 36(45):6883-6891. PMID: 30244873
Background: Pediatric use of pneumococcal conjugate vaccines (PCV) has been associated with significant decrease in disease burden. However, disease caused by non-vaccine serotypes has increased. Safety and immunogenicity of 15-valent...